Adapting off-patent medicines to the specific needs of pediatric populations.

The key objectives of this project are to: 1. Perform a series of clinical studies that will provide sufficient information for a Pediatric Use Marketing Authorisation (PUMA) to be obtained for the use of Risperidone in CD in children and adolescents. 2. Address scientific questions about the moderating and/or mediating factors of the short-term efficacy and maintenance of clinical response, and the short-term and long-term safety of Risperidone in children and adolescents with CD, and the long-term safety of Riseridone in children and adolescents with psychiatric disorders. 3. Disseminate the extension of knowledge acquired by the proposed studies to medical and mental health professionals, tot patients and their families and society in general

Trefwoorden:pediatric population, Risperidone, medicines